Royal Bank of Canada Has $22.68 Million Holdings in Solventum Corporation $SOLV

Royal Bank of Canada lifted its position in shares of Solventum Corporation (NYSE:SOLV) by 47.2% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 347,281 shares of the company’s stock after purchasing an additional 111,419 shares during the quarter. Royal Bank of Canada’s holdings in Solventum were worth $22,678,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. CrossGen Wealth LLC acquired a new stake in Solventum during the 4th quarter worth about $25,000. Measured Wealth Private Client Group LLC acquired a new position in shares of Solventum in the 3rd quarter valued at about $25,000. Clearstead Trust LLC boosted its position in shares of Solventum by 61.0% during the 1st quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock valued at $26,000 after purchasing an additional 150 shares in the last quarter. JNBA Financial Advisors boosted its position in shares of Solventum by 205.4% during the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after purchasing an additional 228 shares in the last quarter. Finally, CYBER HORNET ETFs LLC acquired a new stake in Solventum during the second quarter worth approximately $28,000.

Solventum Stock Performance

NYSE SOLV opened at $87.26 on Thursday. Solventum Corporation has a 52-week low of $62.38 and a 52-week high of $88.65. The company has a 50-day simple moving average of $79.09 and a 200 day simple moving average of $74.36. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.75 and a current ratio of 1.07. The company has a market capitalization of $15.11 billion, a PE ratio of 10.69, a price-to-earnings-growth ratio of 1.36 and a beta of 0.60.

Solventum (NYSE:SOLV) last issued its earnings results on Wednesday, August 5th. The company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.91 by $0.64. Solventum had a return on equity of 23.51% and a net margin of 17.33%.The firm had revenue of $2.21 billion for the quarter, compared to analyst estimates of $2.15 billion. During the same period in the previous year, the company posted $1.69 earnings per share. The business’s revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, research analysts predict that Solventum Corporation will post 6.58 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Piper Sandler lowered their price objective on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. BTIG Research reissued a “buy” rating and set a $91.00 target price on shares of Solventum in a research note on Monday, July 13th. Stifel Nicolaus cut their target price on shares of Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. KeyCorp raised their price target on shares of Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, Wells Fargo & Company decreased their price target on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 6th. Seven analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $86.00.

Trending Headlines about Solventum

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Second-quarter adjusted earnings per share were $2.55, well above analysts’ expectations of approximately $1.90-$1.91. Revenue reached $2.21 billion, exceeding the $2.15 billion consensus estimate. Solventum Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Sales increased 2.2% year over year, while organic sales growth was a stronger 9.5%, suggesting improving underlying demand despite reported revenue growth being affected by portfolio or currency factors. Solventum Q2 Earnings Metrics
• Positive Sentiment: Solventum raised its full-year 2026 guidance, including adjusted EPS of $7.10-$7.20 versus consensus near $6.55-$6.58. The company also increased expectations for organic sales growth and free cash flow, strengthening the earnings outlook. Solventum Raises Profit Forecast
• Neutral Sentiment: The company intends to separate its Health Information Systems business, positioning Solventum as a more focused medical-technology company while allowing the healthcare software unit to pursue its own growth strategy. The move could unlock shareholder value, but investors will watch the separation’s structure, costs and execution. Solventum Health Information Systems Separation

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.